Effects of DPP-4 Inhibition on Triglycerides

NCT ID: NCT01527747

Last Updated: 2023-04-07

Basic Information

• Recruitment Status: SUSPENDED
• Clinical Phase: PHASE4
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-01-31
• Study Completion Date: 2024-12-31

Brief Summary

The purpose of this study is to test the effects of saxagliptin, a treatment for diabetes, on fasting and post-meal blood triglyceride (blood fat) levels.

Detailed Description

This study is designed to help us understand the effects of DPP-4 inhibition on triglyceride levels before and after eating.

Conditions

Type 2 Diabetes; Hypertriglyceridemia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo

Placebo arm

Group Type: PLACEBO_COMPARATOR

Saxagliptin

Intervention Type: DRUG

5 mg daily

Saxagliptin

Active drug arm

Group Type: EXPERIMENTAL

Saxagliptin

Intervention Type: DRUG

5 mg daily

Interventions

Saxagliptin

5 mg daily

Intervention Type: DRUG

Other Intervention Names

Onglyza

Eligibility Criteria

Inclusion Criteria

• Willing to provide signed written informed consent
• Men and women aged 18-80 years
• Type 2 diabetes (as defined by the ADA - see reference 18)
• Baseline HgbA1c between 6.5% and 8%; HgbA1c 7.5-8.0% among subjects taking sulfonylureas
• Baseline plasma triglyceride concentration between 200 and 700 mg/dl
• Stable diabetes medication regimen for at least 12 weeks prior to study entry
• Taking a statin for at least 8 weeks, unless statin therapy is contraindicated or intolerable
• Treatment with other lipid-lowering medications only if the dose has been stable for > 8 weeks.
• Non-smoker
• Body mass index < 45.0 kg/m2
• BP < 140/85
• Normal serum TSH and free T4 concentrations (hypothyroid subjects taking a stable replacement dose of levothyroxine will be allowed if they are biochemically euthyroid)
• Subjects will otherwise be healthy
• Women of child-bearing potential must be willing to use reliable contraception, as defined by our IRB, throughout the study (There are currently no FDA recommended restrictions on the use of saxagliptin in sexually active men, or requirements for contraception in their wives or sexual partners)
• Able and willing to complete study procedures

Exclusion Criteria

• Transaminase concentrations > 2 times the ULN. (Mild elevations of AST and ALT will be allowed up to 2x ULN at baseline if there is no evidence of viral hepatitis or intrinsic liver disease. Since many of these subjects may have some degree of hepatic steatosis, a key intervention is the implementation of treatment to lower glucose and triglycerides)
• Estimated creatinine clearance < 60 ml/min
• Microalbumin-creatinine ratio > 120
• Alcohol consumption > 1 drink daily in women and > 2 drinks daily in men
• Pancreatitis within the preceding 6 months
• Type 1 diabetes
• History of diabetic ketoacidosis (DKA)
• Cardiovascular disease (CAD, stroke, PVD)
• Known human immunodeficiency virus (HIV) infection
• Viral hepatitis
• Pregnancy or lactation
• A current diagnosis of active non-dermatologic cancer
• Other life-threatening illness
• History of small bowel resection or gastric bypass surgery
• Use of glucocorticoid medications, beta blockers, thiazide diuretics, excess alcohol intake (beta-blockers and thiazide diuretic will be allowed, if necessary, if the dose has been stable for > 12 weeks prior to study entry and the dose will remain stable throughout the study. Complete exclusion of these drugs would exclude a substantial proportion of diabetic patients)
• Use of systemic cytochrome P450 3A4 (CYP 3A4/5) inhibitors such as ketaconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir and telithromycin.
• Current enrollment in another research study or use of any investigational drug within 90 days of study entry
• Other medical conditions that may interfere with participation in the study, in the opinion of the investigator

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Oregon Health and Science University

OTHER

Sponsor Role: lead

Responsible Party

P. Barton Duell, M.D.

Director, Lipid-Atherosclerosis Laboratory

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

P Barton Duell, MD

Role: PRINCIPAL_INVESTIGATOR

Oregon Health and Science University

Locations

Oregon Health & Science University

Portland, Oregon, United States

Countries

United States

Other Identifiers

CV181-142

Identifier Type: -

Identifier Source: org_study_id